Background And Aims: Statins suppress hepatic mRNA expression of ANGPTL3 encoding angiopoietin-like 3 in healthy subjects, but it is unknown if plasma ANGPTL3 concentrations are affected by statins prescribed to hypercholesterolemic patients in clinical practice. We therefore investigated the effect of statin treatment on plasma ANGPTL3 concentrations in hypercholesterolemic patients. In addition, we explored the underlying mechanism by which statins regulate ANGPTL3 in vitro.
Methods: Plasma ANGPTL3 concentrations were measured in 93 genetically confirmed familial hypercholesterolemia (FH) patients who were using statin therapy and 61 statin naïve FH patients. Moreover, concentrations were measured in 14 hypercholesterolemic patients who discontinued their statin treatment for 4 weeks. In vitro studies were performed with Huh7 human hepatoma cells.
Results: Plasma ANGPTL3 concentrations were 15% lower in statin treated FH patients compared to statin naïve FH patients (145 (120-193) vs. 167 (135-220) ng/ml, p = 0.012). Statin discontinuation resulted in a 21% (p<0.001) increase of plasma ANGPTL3 concentrations. Simvastatin reduced ANGPTL3 mRNA expression and ANGPTL3 secretion of Huh7 cells. Liver X receptor (LXR) activation with T0901317 increased ANGPTL3 mRNA expression and ANGPTL3 secretion by 6- and 3-fold, respectively. Adding simvastatin did not mitigate this effect but adding the LXR antagonist GSK2230 to simvastatin-incubated Huh7 cells diminished simvastatin-induced reductions in ANGPTL3 mRNA expression and ANGPTL3 secretion. Simvastatin reduced intracellular oxysterol concentrations. Oxysterols are endogenous LXR ligands, implying that simvastatin suppresses ANGPTL3 secretion via reduced oxysterol-mediated LXR activation.
Conclusions: Statins lower plasma ANGPTL3 concentrations in hypercholesterolemic patients, likely due to decreased oxysterol-mediated LXR activation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.atherosclerosis.2020.11.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification and Evaluation of Angiogenesis-Related Proteins That Predict Major Adverse Cardiovascular Events in Patients with Peripheral Artery Disease.
J Cardiovasc Dev Dis
December 2024
Department of Surgery, University of Toronto, Toronto, ON M5S 1A1, Canada.
Background: The most common cause of death in patients with peripheral artery disease (PAD) are major adverse cardiovascular events (MACEs), including myocardial infarction (MI) and stroke. However, data on biomarkers that could be used to help predict MACEs in patients with PAD to guide clinical decision making is limited. Angiogenesis-related proteins have been demonstrated to play an important role in systemic atherosclerosis and may act as prognostic biomarkers for MACEs in patients with PAD.
View Article and Find Full Text PDFFamilial chylomicronemia: New perspectives.
Clin Investig Arterioscler
December 2024
Unidad de Lípidos y Riesgo Cardiovascular, Servicio de Medicina Interna, Complejo Hospitalario Universitario de A Coruña, A Coruña, España. Electronic address:
Familial chylomicronemia syndrome (FCS) is a very rare, underdiagnosed disorder that can cause abdominal pain and recurrent pancreatitis from childhood -potentially life-threatening- and chronic complications such as diabetes mellitus and exocrine pancreatic insufficiency. FCS affects the quality of life and mental health of those who suffer from it, aspects that must be taken into account in its treatment, based on a strict low-fat diet, which is difficult to adhere to and persist. People with FCS lack the lipolytic capacity to hydrolyze triglycerides (TG) and have a minimal or null response to conventional lipid-lowering treatments.
View Article and Find Full Text PDFAssociations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality.
Circulation
October 2024
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN (Y.Q.C., H.L., D.L., Y.W., E.Y.Z., Y.Q., R.J.K.).
Article Synopsis
- ANGPTL3/4/8 proteins regulate lipoprotein lipase (LPL) activity, with ANGPTL8 forming complexes that influence ANGPTL4's function; however, their association with cardiovascular outcomes is under-researched.
- This study involved measuring various ANGPTL proteins and complexes in two large population studies (LURIC and getABI) focusing on cardiovascular health and outcomes over several years.
- Findings showed that while ANGPTL3/8 inhibited LPL activity and correlated with increased LDL-C and triglycerides, they did not predict cardiovascular death; however, ANGPTL4/8 and CD-ANGPTL4 were linked to higher diabetes prevalence and increased cardiovascular mortality risk.
Article Synopsis
- Abdominal aortic aneurysm (AAA) is a serious vascular disease that currently lacks effective treatments, prompting research into its causative factors.
- This study used genetic, proteomic, and metabolomic approaches along with mouse models to show that high levels of triglycerides (TG) contribute significantly to the development and rupture of AAA.
- The findings highlight that managing triglyceride-rich lipoproteins could be crucial for treating AAA and suggest that targeting TG pathways may inhibit AAA progression.
Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and untreated with lipoprotein apheresis.
J Clin Lipidol
November 2024
Medical School (Drs Chan, Watts), University of Western Australia, Perth, Australia; Cardiometabolic Service (Dr Watts), Department of Cardiology and Internal Medicine, Royal Perth Hospital, Perth, Australia.
Article Synopsis
- Evinacumab is a new treatment for patients with homozygous familial hypercholesterolemia (HoFH) that inhibits ANGPTL3, potentially reducing reliance on lipoprotein apheresis (LA) for lowering LDL cholesterol levels.
- A study assessed its long-term safety and efficacy in 7 HoFH patients over 36 months, showing significant LDL-C reductions of -43.4% and -54.2% at 30 and 36 months, respectively.
- Patients tolerated evinacumab well, reporting it to be less demanding than LA, and they experienced quality of life scores similar to the general population in Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!